Cassava Sciences Inc News - SAVA

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

$126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer’s Disease...

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a...

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

End-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ.Monday, May...

Redemption Date Announced for Warrants

Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist...

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database...

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In...

Form 8-K - Current report

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam...

👍️0

PonkenPlonken 3 weeks ago

Maybe they can save the company by saying they will turn into an AI drug discovery company and put their cash in BTC?
LOL

👍️0

ranchhand71 3 weeks ago

Delusional!

👍️0

sunspotter 3 weeks ago

Yes, a company founded and run by fraudsters with a drug that doesn’t work.

What could possibly go wrong?

👍️0

ttottip 3 weeks ago

It's worth it to take a position here. There's a chance for rebound here.

😂 1

ranchhand71 3 weeks ago

In SEC 144 filing CFO using Morgan Stanley to sell SAVA stock . Saying he knows no material info!!!! Hmmm..

👍️0

PonkenPlonken 3 weeks ago

You are most welcome.
Maybe he is good at sniffing out security fraudsters and crooks because he knows how to think like them.
Regards...

👍️0

TheFinalCD 3 weeks ago

THANKS for the reply

I cant stand that weirdo either

he just happened to make a good call on $SAVA whether it was really him or not

who knows

👍️0

tredenwater2 4 weeks ago

What about the director who poured millions into Cassava propping it up when it would crash from bad news? If this was a scam, wouldnt he have known about it?

👍️0

PonkenPlonken 4 weeks ago

That also baffled me. Many smart people had their money tied up here and somehow the share price recovered after the court cases in September. Id love to know more about the why.
They didnt see the forest for all the trees?

👍️0

PonkenPlonken 4 weeks ago

I can only agree. Shkreli still has friends in the industry that likely told him about all of his "DD" that he presented in this rink dink "paper" then earns the laurels.
98% of PH3 Alzheimer trials miss and this one had many sticks in the soup. --> managements history of lying and no peer reviewed literatue backing.
Unbelievable there is this laughable antihero worshipping around his persona. Nothing fabulous about this sociopath.

👍️ 1

Hoskuld 4 weeks ago

I made the same call repeatedly over the last 2 years but didn't get the love that the convicted fraudster is getting!

👍️ 1

ranchhand71 4 weeks ago

How long before indictments of former CEO and his wife? Class action suit? Who sold with inside info this past Friday?

👍️0

TheFinalCD 4 weeks ago

I dont like him but he made a good pre P3 call
if somehow it passed P3 it could have went up slot
P3 fail it crashed

Im listening to him talk about shorting MSTR against BTC hedge/arbitrage
https://x.com/i/broadcasts/1LyxBgywQZkKN

👍️0

MartinLutherKing 4 weeks ago

Last call all aboard SAVA FDA fast track status Micro RNA novel prize cancer destruction RNAZ

👍️0

PonkenPlonken 4 weeks ago

When companies split in ways that put them this far above the minimum requirement they usually do so when they expect much more downside and when they want to cater to the low float crowd instead of real investors in the bio space.

👍️0

PonkenPlonken 4 weeks ago

Thank you. Someone forwarded this to me, else i wouldnt have anticipated something like that :)
Im not interested in ESPR right now as its really in no mans land. I dont "hold" many bios at all. The market has been brutal past few months. But there are some 70 stocks i monitor daily for action...

👍️0

FooBarAndGrill 4 weeks ago

$PGHL. Wow! Ran 918% during market hours. AH down 87%.
The opposite of a bear raid.
Prada
9 hours ago

So what happened? I’ll tell you….

Short sellers need only be outside of margin compliance for a fraction of a second for brokers to force automatic buy-ins. Knowing this, offshore scam operators tightly control the float of all these issuers but sometimes leave borrow available to lure in short sellers...

When short sellers bite, the scam operators wash trade a spike in the stock, then keep bid/asks moving during the halt so no unhalt price can be settled upon during regular trading hours. Then, after hours, it unhalts as they rip the price 10x+, causing brokers to force-liquidate accounts that were short. Brokers buy-in to cover the short sales as scam artists sell into the artificially high price.

This can lead to short accounts being wiped out instantly and can even lead to broker losses. The same liquidation scam playbook had been executed previously with other Nasdaq offshore scam tickers such as $ZJYL.

👍️0

dinogreeves 4 weeks ago

This is terrible

https://finance.yahoo.com/quote/PGHL/

👍️0

dinogreeves 4 weeks ago

So much for that former insider/fraudster of KBI*O then turned into another turd HYG*N. But altogether, SAVA has been a scam, any public company that works with Maxim is a scam. Period.

👍️ 1

janice shell 4 weeks ago

Yes indeed!

👍️0

FACT-MASTER 4 weeks ago

Exactly.

Nice chatting with you Janice.

👍️0

janice shell 4 weeks ago

Yes, I was surprised to learn kidney beans are somewhat toxic. Toxic enough that you should never cook them in the water you soaked them in. I wouldn't have known were I not an inveterate reader of packaging.

👍️0

FACT-MASTER 4 weeks ago

Cassava, from what i have seen, is ingrained into the cultures of Mexican / African / South American diets and they are proud of it.

Their persistence, imo comes from a lack of alternatives and again a culture practice of growing a usable and edible product. Visiting some places in Mexico / Brazil you begin to understand people are just in "survival" mode - use what's available.

The toxicity issue is also common in legume crops such as lima / red kidney beans which are also common in these cultural diets.

👍️0

janice shell 4 weeks ago

And it was first done by pretty primitive people.

👍️0

nsomniyak 4 weeks ago

Cocoa beans taste pretty crappy before you run them through a 15 step process to get chocolate...Another case of " how did they get from this raw stuff to that?"

👍️0

janice shell 4 weeks ago

Yes, it was an unusual choice of name. Though it's a popular carbohydrate in Central and South America, perhaps the most popular. I've always wondered how many people died before they figured out how to prepare it. And why they were so persistent.

👍️0

FACT-MASTER 4 weeks ago

Interesting, just like cassava, which when raw, contains cyanide and is toxic.

https://www.medicalnewstoday.com/articles/323756#is-it-toxic

The name picked by scammers for scammers - how suitable!

Now let's see , where is cassava grown? Mexico / Costa Rica / South America. Insiders probably went straight to the airport after the reverse split, never to be seen again, unless of couse Karma catches up to them, amen.

Appreciate the "scam force" here on Ihub - H Bear too.

👍️0

janice shell 4 weeks ago

Hello again! I found this one remarkable because it was KNOWN that the most important insiders were scammers. And people seem simply to have discounted that, somehow imagining what they produced would be a winner.

👍️0

FACT-MASTER 4 weeks ago

Why, hello janice!

Our paths have not crossed for a long time.

Yes, investors still gett'in burnt, will it ever end !? i think not, even i , have had to learn a few lessons from my foolish juvenile days. (lol)

👍️0

FACT-MASTER 4 weeks ago

Comprende amigo,

"Its possible for mortals to anticipate a partner in a ph1/ph2 company when their data is about to be due and a BP dropped similar but not equal programs recently"

(cost efficient for a BP to partner up with a smaller biotech demonstrating a superior product in the same category)

The reverse can also be true - eg IMTX, BMY drops out of 1 trial, IMA402 p1/p2 results are poor - same press release in that instance. Was suspicion evident in previous trading - i beleive so, however, hindsight is 20/20

👍️0

janice shell 4 weeks ago

Seriously, did anyone need Shkreli to tell them it was doomed? The follies of management should have been enough.

👍️ 1

FACT-MASTER 4 weeks ago

Congrats on your short here with SAVA.

Your education paid off big time in this instance!

We should probably discuss ESPR further on that board, of course if you are up to that.

👍️0

FACT-MASTER 4 weeks ago

Reminds me of of ARGS - that was a stinging lesson for me, ouch...still hurts!

Although i feel bad for investors in SAVA, biotech is high risk and that should be understood by all investors. Lawsuit won't help imo, ... prove wrongdoing against forward looking statements, etc, etc, for 5+ years, imo. - only good for the lawyers, imo.

Ref: Argos Therapeutics

👍️0

TheFinalCD 4 weeks ago

https://x.com/MartinShkreli/status/1859681514415607930

👍️0

MartinLutherKing 4 weeks ago

You will all kiss my feet brothers make it all back

👍️0

MartinLutherKing 4 weeks ago

Get ready for Fda fast track status for nobel prize micro rna for terminally ill cancer patients

👍️0

MartinLutherKing 4 weeks ago

A reverse split is NOT something directors or management wishes to do — we all hope it won’t be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing did so on the condition that our shareholders authorize a reverse split — should one be necessary. The reverse split will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024.

👍️0

PonkenPlonken 4 weeks ago

I have never ever in my life seen a great bio with a chart like this.
SCREAMS promotion campaign - which is something you dont do when you have the next greatest thing in oncology.
Now a 1 for 33 is coming??

"The reverse split will reduce the number of shares of common stock outstanding from 17,265,658 shares to approximately 523,202 shares." per their recent PR. They want to cater to the low float crowd.
A more healthy ratio wouldve done it too...

👍️0

MartinLutherKing 4 weeks ago

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
October 23 2024 - 7:00AM

Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the second cohort of patients based on its favorable review of Cohort 1 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer. All patients in the first cohort remain on study for continued treatment. No significant safety or dose limiting toxicities have been reported. The dose administered to the second cohort will be approximately double the dose administered to the first cohort.
“An SRC is a group of clinicians and experts that oversee the safety of subjects during the conduct of the trial. The SRC makes decisions on whether and how the study should proceed, including dose escalation and de-escalation decisions per the study design. The recommendations of the SRC are used to decide whether a clinical trial should be continued as designed, changed, or terminated,” commented Sue Duggan, TransCode’s Senior Vice President of Operations. Duggan added, “No dose-limiting toxicities were reported in the first cohort of patients treated with TTX-MC138. Eligible subjects may now be scheduled in Cohort 2 for treatment with the next dose level of TTX-MC138.”

👍️0

MartinLutherKing 4 weeks ago

Is FDA And NIH Ascam
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
September 05 2024 - 7:00AM

Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, TransCode’s lead therapeutic candidate. TransCode has recently activated three clinical trial sites to conduct a Phase I/II clinical trial of TTX-MC138 for the treatment of advanced solid tumors.

The clinical trial is designed to generate critical data to support evaluation of the safety of TTX-MC138. While efficacy of TTX-MC138 is not an endpoint in this trial, the trial may nevertheless provide early evidence of TTX-MC138 clinical activity in patients with metastatic disease. Funds under the grant are expected to be received over two years.

“We are honored that the NIH recognizes and continues to support our mission to advance therapies against metastatic cancer,” said Zdravka Medarova, Ph.D., Chief Scientific Officer of TransCode. “NIH funding is awarded only after rigorous review. We believe that this award attests to the potential impact, novelty, and robustness of the TTX-MC138 clinical development program.”

TTX-MC138 is a first-in-class therapeutic candidate with novel relevance to metastatic disease. Successful clinical development of TTX-MC138 potentially represents a viable treatment option for many patients with metastatic cancer.

👍️0

MartinLutherKing 4 weeks ago

RNAZ FDA Fast track status in progress, they are making everyone panic sell, read between the lines brother, you will kiss my feet and make all your $$ back and more

👍️0

PonkenPlonken 4 weeks ago

I was short SAVA.
And believe RNAZ is a scam.

👍️ 1

MartinLutherKing 4 weeks ago

last call for RNAZ cancer cure fda fast track coming about to unleash hell on shorts

👍️0

rbl100 4 weeks ago

Good. But I am glad I sold @ $4.26 yesterday. I am not a member of Congress who gets info. and can inside trade. Ever wonder how a women who's net worth was $319,000 joins Congress and in 4 years her net worth is now $46 Million? They get into Congress and are allowed to inside trade. That's how.

👍️0

rbl100 4 weeks ago

Correct. But there is no one home.

👍️0

PonkenPlonken 4 weeks ago

I agree. I was very fortunate to learn from a professional in the bio sector. He taught me that its crucial to understand whats actually being discussed in the share price.
Sometimes, you have very seggsy risk reward ratios......... Where stocks correct upwards.

👍️ 1

John_Vallay 4 weeks ago

This is the world we live in when it comes to biotech investing.
Every day is a positive day as long as the company is moving forward and trying to get data that shows promising results. During this long period some stocks go up, some go down but the positivity and promise is there for all investors to hold onto and keep the dream alive.

Then the data comes out and it is not good, or FDA says no.

That is biotech investing - purely speculative with absolutely no control by the management team, other than hurting the stock price during the process with poor deals that are some form of toxic financing.

Biotech investing is not for the faint of heart.

👍️0

PonkenPlonken 4 weeks ago

Just in: SRPT to give 850mn upfront in partnership with ARWR...
Another AAV based gene tx seeking RNAI......

👍️0

PonkenPlonken 4 weeks ago

I dont know much about Rett but I like their miRARE + aav9 to manage precise mecp2 expression... I like this RNA thermometer/thermostat function. I believe its the way to go.
Whether they will succeed or the stock go up? I dont know.

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Cassava Sciences Inc (SAVA)

Empower your portfolio: Real-time discussions and actionable trading ideas.

SAVA News

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

Redemption Date Announced for Warrants

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Form 8-K - Current report

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

Form CERT - Certification by an exchange approving securities for listing

SAVA Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Cassava Sciences Inc (SAVA) News

Cassava Sciences Inc (SAVA)

Empower your portfolio: Real-time discussions and actionable trading ideas.

SAVA News

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

Redemption Date Announced for Warrants

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Form 8-K - Current report

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

Form CERT - Certification by an exchange approving securities for listing

SAVA Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free